CDK-TCIP2
DK-TCIP2, linking inhibitor of CDK9 SNS-032 with ligands of BCL6 BI-3812 (HY-111381), is a anticancer agent. DK-TCIP2 shows anticancer activity in vivo and in vitro and can be used for study of lymphoma cancer[1].
Product Specifications
UNSPSC
12352005
Target
BCL6; CDK
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Immunology/Inflammation
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/cdk-tcip2.html
Purity
98.94
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C1C(OCC(NC)=O)=CC2=C(N1C)C(OC)=CC(NC3=NC(N4CCC(CC4)C(N5CCC6(CCN(C(CN7CCC(CC7)C(NC8=NC=C(SCC9=NC=C(C(C)(C)C)O9)S8)=O)=O)CC6)CC5)=O)=NC=C3Cl)=C2
Molecular Formula
C52H67ClN12O8S2
Molecular Weight
1087.75
References & Citations
[1]Sarott RC, et al. Relocalizing transcriptional kinases to activate apoptosis. Science. 2024 Oct 4;386 (6717) :eadl5361.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
![BCL2 (41-54) Mouse Monoclonal Antibody [Clone ID: 100/D5]](https://cdn.genprice.uk/products/937/68dd189e061270361e8fd4a4/imageurl/am33245pu-t.webp)
BCL2 (41-54) Mouse Monoclonal Antibody [Clone ID: 100/D5]
TNFS15 / VEGI (Vascular Endothelial Growth Inhibitor) (VEGI/2052R), CF647 conjugate, 0.1mg/mL
